At the European Academy of Dermatology and Venereology Congress, data was presented from a phase 2 trial involving 64 patients showing that treatment with ruxolitinib cream was effective in reducing the signs and symptoms of cutaneous lichen planus, including itch and skin pain. Ruxolitinib cream was well tolerated and resulted in significant improvements in disease severity after 16 weeks of treatment. The results suggested that this topical treatment could be a promising option for patients with cutaneous lichen planus, which affects roughly 2% of the population. The study was funded by Incyte Corporation, and researchers are hopeful for FDA approval of this treatment in the future.
Source link
Ruxolitinib Cream Shows Promise in Treating Lichen Planus
